Recently, ZLDI‐8 was reported as a novel ADAM‐17 inhibitor involved in enhanced chemotherapeutic effects of sorafenib in hepatocellular carcinoma cells [34]. The gene discussed is ADAM17; the disease is hepatocellular carcinoma.